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licenses/by-nc-nd/4.0/).Rationale & Objective: Chronic kidney disease
(CKD)-associated pruritus, generalized itching
related to CKD, affects many aspects of hemodi-
alysis patients’ lives. However, information
regarding the relationship between pruritus and
several key outcomes in hemodialysis patients re-
mains limited.
Study Design: Prospective cohort.
Setting & Participants: 23,264 hemodialysis pa-
tients from 21 countries in the Dialysis Outcomes
and Practice Patterns Study (DOPPS) phases 4 to
6 (2009-2018).
Exposure: Pruritus severity, based on self-reported
degree to which patients were bothered by itchy
skin (5-category ordinal scale from “not at all” to
“extremely”).
Outcomes: Clinical, dialysis-related, and patient-
reported outcomes.
Analytical Approach: Cox regression for time-to-
event outcomes and modified Poisson regression
for binary outcomes, adjusted for potential
confounders.
Results: The proportion of patients at least
moderately bothered by pruritus was 37%, and 7%42were extremely bothered. Compared with the
reference group (“not at all”), the adjusted mortality
HR for patients extremely bothered by pruritus was
1.24 (95% CI, 1.08-1.41). Rates of cardiovascular
and infection-related deaths and hospitalizations
were also higher for patients extremely versus not
at all bothered by pruritus (HR range, 1.17-1.44).
Patients extremely bothered by pruritus were also
more likely to withdraw from dialysis and miss
hemodialysis sessions and were less likely to be
employed. Strong monotonic associations were
observed between pruritus severity and longer
recovery time from a hemodialysis session, lower
physical and mental quality of life, increased
depressive symptoms, and poorer sleep quality.
Limitations: Residual confounding, recall bias,
nonresponse bias.
Conclusions: Our findings demonstrate how
diverse and far-reaching poor outcomes are for
patients who experience CKD-associated
pruritus, specifically those with more severe
pruritus. There is need for change in practice
patterns internationally to effectively identify and
treat patients with pruritus to reduce symptom
burden and improve quality of life and possibly
even survival.Chronic kidney disease (CKD)-associated pruritus,generalized itching related to CKD, affects many pa-
tients with advanced CKD1,2 and patients with end-stage
kidney disease receiving dialysis.3-9 In 2006, a large
international study of hemodialysis (HD) patients partici-
pating in the Dialysis Outcomes and Practice Patterns Study
(DOPPS) showed that 45% and 42% of patients receiving
HD from 1996 to 1999 and from 2000 to 2003, respec-
tively, experienced moderate to extreme pruritus,3 though
studies have shown that pruritus in general can affect up to
87% of patients receiving dialysis.10 Based on more recent
DOPPS data, Rayner et al4 have shown that the prevalence
of moderate to extreme pruritus remained high at 37% in
2012 to 2015, ranging from 26% in Germany to 48% in
the United Kingdom.
Prior studies have demonstrated that CKD-associated
pruritus causes distress in HD patients that ranges from
sporadic discomfort to complete restlessness11; contributes
to restless sleep, agitation, and depression4; and has been
associated with increased mortality.3,12,13 These studies
underscore the importance of better defining the presence
of pruritus and its impact on the lives of HD patients. Inaddition to these outcomes, studies have also demonstrated
an association between pruritus and worse kidney disease
burden scores, as well as poorer health-related quality of
life (HR-QoL).3,8,14-16 The pathophysiology of pruritus
remains unclear.11,17-19
In addition to skin emollients, hydrating creams,
and UV light therapy, proposed medications have
included antihistamines, gabapentin, pregabalin, and
nalfurafine,18,20-24 but there are limitations to these
studies and pruritus often remains inadequately
treated, although research on emerging therapies is
ongoing.25
Data are lacking on how pruritus affects other clinical,
dialysis-related, and patient-reported outcomes (PROs). In
this study, we used a large contemporary international
sample of patients receiving HD to describe the prevalence
of pruritus by patient-reported severity and by country and
to investigate associations of pruritus severity with mor-
tality, hospitalizations, and clinical outcomes including
withdrawal from dialysis, missed dialysis treatments, re-
covery time from a dialysis session, HR-QoL, and
employment status.Kidney Med Vol 3 | Iss 1 | January/February 2021
PLAIN-LANGUAGE SUMMARY
Chronic kidney disease–associated pruritus (itch)
significantly affects many hemodialysis patients but
much is still unknown. We analyzed associations be-
tween itch severity and several key outcomes in a large
international sample of hemodialysis patients between
2009 and 2018. Itching was associated with higher risk
for mortality, while patients extremely bothered by
itching were more likely to withdraw from dialysis and
miss hemodialysis sessions and less likely to be
employed compared with those not bothered. We
showed strong associations between increasing itch
severity and longer recovery time from a hemodialysis
session, lower physical and mental quality of life,
increased depressive symptoms, and poorer sleep
quality. There is a clear need for change in practice
patterns to reduce the symptom burden of itch and
improve quality of life.
Sukul et alMETHODS
Data Source
The DOPPS is an international prospective cohort study of
patients 18 years or older treated with in-center HD in 21
countries. Maintenance HD patients were randomly
selected from national samples of HD facilities in each
country; detailed information is included in prior publi-
cations26,27 and at http://www.dopps.org. Study approval
and patient consent were obtained as required by national
and local ethics committee regulations. This analysis
included data from DOPPS phase 4 (2009-2011), phase 5
(2012-2015), and phase 6 (2015-2018) in all DOPPS
countries with available data.Variables
Our exposure variable was patient response to a single
question (of 12) included in the Symptoms and Problems
subscale of the Kidney Disease Quality of Life 36-item
short form survey (KDQOL-36)28 component of the self-
administered patient questionnaire: During the past 4
weeks, to what extent were you bothered by itchy skin?
Response options were not at all, somewhat, moderately,
very much, and extremely.
Several outcomes were investigated and are summarized
in Figure 1. Outcomes were grouped into 3 categories:
clinical outcomes, dialysis-related outcomes, and PROs.
The primary clinical outcome was time to all-cause
mortality. Other clinical outcomes included cardiovas-
cular (CV) and infection-related death, all-cause and
cause-specific hospitalizations including CV, infection,
skin-related (ie, cellulitis/skin infection, rash, or other
unspecified skin-related diagnosis), and “mental status
change/confusion” admissions. HD facilities notKidney Med Vol 3 | Iss 1 | January/February 2021reporting hospitalizations or cause of death were
excluded from these analyses. A listing of causes of death
and hospitalization diagnosis/procedure codes is pre-
sented in Table S1.
Dialysis-related outcomes included withdrawal from
dialysis, missed/skipped HD treatments, employment, and
recovery time from an HD session. Patients were consid-
ered to have withdrawn from dialysis if their cause of
death or reason cited for leaving DOPPS was listed as
“withdrawal from dialysis.” All patients who withdrew
from dialysis died following their withdrawal. Countries
with withdrawal rates < 0.01 (China, the Gulf Cooperation
Council countries [Bahrain, Kuwait, Oman, Qatar, Saudi
Arabia, and United Arab Emirates], Germany, Italy, Japan,
Russia, and Turkey) were not included in this analysis. The
number of missed treatments in each of the past 4 months
was abstracted from medical records; patients were
considered to have missed or skipped treatments if they
missed at least 2 treatments during the past 4 months.
Countries with missed treatment rates <0.01 (Italy, Japan,
and Turkey) were not included in this analysis; further,
missed treatments were only captured in DOPPS phases 5
and 6 (not phase 4). Employment status was abstracted
from medical records and was defined as full- or part-time
employment, restricted to patients younger than 65 years.
Self-reported recovery time from an HD session was
assessed on the patient questionnaire by the question,
“How long does it take you to recover from a dialysis
session?”29 Response options were less than 2, 2 to 6, 7 to
12, and more than 12 hours, and we dichotomized the
outcome at 6 hours.
PROs included measures of HR-QoL, depression, sleep
quality, faintness/dizziness, and feeling washed out/
drained. Mental (MCS) and Physical Component Sum-
mary (PCS) scores (higher = better HR-QoL) were
derived from the 12-Item Short Form Health Survey,
a subset of the KDQOL-36.28 The Center for Epidemi-
ologic Studies-Depression (CES-D) score was derived
from the 10-item CES-D Boston form while maintain-
ing the 4 response categories used in the 20-item CES-
D Yale form for greater precision; a score ≥ 10 on the
30-point scale is indicative of depressive symptoms.30
Sleep quality was assessed on the patient question-
naire by the CES-D question, “During the past week,
how often did you feel your sleep was restless?”
Response options were: 0, 1 to 2, 3 to 4, and 5 to 7
nights per week, and we considered 3+ nights as poor
sleep quality. Faintness/dizziness and feeling washed
out/drained were each assessed by a single question
from the KDQOL-3628 asking about the extent of
bother from each of these factors during the past 4
weeks; response options were the same as for the itchy
skin question, and we defined the outcome as at least
moderately bothered.
Information on patient demographics and comorbid
condition history was abstracted from medical records at43
34,694 patients in DOPPS phases 4-6 (2009-2018) in HD facilities administering patient questionnaires (PQ)
• 98 patients excluded – no follow-up for mortality
• 10,129 patients excluded – did not complete a PQ
• 1,203 patients excluded – completed a PQ but did not respond to the question 
regarding extent bothered by itchy skin (primary exposure variable)
23,264 patients eligible for analysis of primary outcome: all-cause mortality
Secondary analyses
Outcome N eligible* Definition
Clinical outcomes Cause of death 23,202 Cardiovascular (CV) and infection related
Hospitalization 22,586 All-cause, CV, infection, skin-related, mental status change
Dialysis-related 
outcomes
Withdrawal from HD 10,784 Voluntary discontinuation of dialysis therapy prior to death
Missed HD treatments 6,492 Missed/skipped at least 2 HD sessions in next 4 months
Employment 9,979 Employed full-time or part-time, among age < 65 years
Recovery time from HD 16,917 Self-reported time to recover from an HD session > 6 hours
Patient-reported 
outcomes (PROs)
PCS and MCS 18,753 Physical and Mental Component Summary of the SF-12
CES-D 10 19,526 Center for Epidemiologic Studies-Depression score (range: 0-30)
Poor sleep quality 22,464 Self-reported restless sleep at least 3 nights/week
Faintness / dizziness 22,631 At least moderately bothered by faintness or dizziness
Washed out / drained 22,484 At least moderately bothered by feeling washing out or drained
Figure 1. Flow chart of inclusion/exclusion criteria for primary analysis and list of secondary outcomes. *Number of eligible patients
for each secondary analysis varies based on data availability of each outcome variable, as detailed in Methods. Abbreviations: CES-D,
Center for Epidemiologic Studies-Depression; DOPPS, Dialysis Outcomes and Practice Patterns Study; HD, hemodialysis; MCS,
Mental Component Summary; PCS, Physical Component Summary; SF-12, 12-Item Short Form Health Survey.
Sukul et alDOPPS enrollment in each study phase. Laboratory mea-
sures and catheter use were updated monthly and selected
based on closest proximity to the completed patient
questionnaire.
Statistical Analysis
We first described patient characteristics of the study
population and compared included versus excluded pa-
tients to assess how patient questionnaire nonresponders
may differ from responders. We also compared patient
characteristics by degree of self-reported pruritus. The
distribution of the exposure variable was summarized
overall and by DOPPS country.
Associations between pruritus and time-to-event out-
comes (clinical outcomes + withdrawal from dialysis)
were assessed using Cox regression models, stratified by
DOPPS phase and country, and using a robust sandwich
covariance estimator to account for facility clustering.
Time at risk began at the time of patient questionnaire
completion and ended at the time of the event of in-
terest, 7 days after leaving the facility due to transfer or
change in modality, loss to follow-up, or administrative
end of study phase (whichever occurred first).44Proportional hazards assumptions were checked by ex-
amination of log-log survival plots. Because odds ratios
will not approximate risk ratios when the outcome is not
rare, we instead presented prevalence ratios to estimate
the associations between pruritus and binary outcomes
(≥2 missed treatments, employment, recovery time > 6
hours, CES-D score ≥ 10, poor sleep quality, faintness/
dizziness, and washed out/drained). Because a log-
binomial regression approach failed to converge, a
problem frequently encountered,31 we used a modified
Poisson regression approach, a valid alternative when
log-binomial regression fails to converge.32 Associations
between pruritus and normally distributed outcomes
(PCS and MCS scores) were assessed using linear mixed
models with a random facility intercept to account for
clustering.
All models accounted for facility clustering using robust
variance estimators and were adjusted for the following
potential confounders: DOPPS phase and country, age, sex,
vintage, body weight (postdialysis), catheter use, 15
summary comorbid conditions (listed in Table 1), serum
albumin level, hemoglobin level, and serum phosphorus
level.Kidney Med Vol 3 | Iss 1 | January/February 2021
Table 1. Patient Characteristics by Degree of Self-reported Pruritus
Patient Characteristic N
Self-reported Extent Bothered by Itchy Skin
Not at All Somewhat Moderately Very Much Extremely
No. of patients 23,264 7,665 (33%) 7,009 (30%) 4,258 (18%) 2,711 (12%) 1,621 (7%)
Case-mix
Age, y 23,207 63.6 ± 14.7 63.2 ± 14.4 64.5 ± 14.4 64.7 ± 14.4 64.7 ± 14.4
Male sex 23,248 4,647 (61%) 4,322 (62%) 2,679 (63%) 1,681 (62%) 992 (61%)
Vintage, y 23,05 2.5 [0.7-6.1] 2.8 [0.9-6.4] 2.7 [0.8-6.2] 2.6 [0.7-6.0] 2.5 [0.8-6.0]
Postdialysis weight, kg 22,794 71 ± 19 69 ± 19 70 ± 20 70 ± 19 69 ± 20
Treatments
IDWL, % of body weight 22,769 2.8 ± 1.4 3.1 ± 1.4 3.0 ± 1.4 3.1 ± 1.4 3.2 ± 1.4
Single pool Kt/V 18,777 1.51 ± 0.32 1.47 ± 0.32 1.48 ± 0.33 1.47 ± 0.33 1.45 ± 0.32
<3 HD sessions/wk 23,067 301 (4%) 320 (5%) 204 (5%) 102 (4%) 60 (4%)
Catheter use 21,150 1,488 (21%) 1,099 (17%) 840 (22%) 500 (20%) 352 (24%)
Hemodiafiltration 23,048 1,356 (18%) 1,062 (15%) 677 (16%) 411 (15%) 247 (15%)
ESA use 22,499 6,324 (85%) 5,836 (86%) 3,510 (85%) 2,257 (86%) 1,355 (87%)
ESA dose, 1,000 U/wk) 18,029 7.0 [4.0-12.0] 7.4 [4.0-11.5] 7.5 [4.5-12.0] 7.5 [4.5-12.0] 8.0 [5.0-12.5]
Laboratory values
Hemoglobin, g/dL 22,768 11.2 ± 1.4 11.1 ± 1.4 11.1 ± 1.4 11.0 ± 1.5 10.9 ± 1.5
Serum albumin, g/dL 21,844 3.72 ± 0.48 3.73 ± 0.46 3.68 ± 0.48 3.66 ± 0.48 3.60 ± 0.50
Serum creatinine, mg/dL 22,562 8.4 ± 2.9 9.1 ± 3.0 8.7 ± 3.0 8.6 ± 3.1 8.6 ± 2.9
C-Reactive protein, mg/L 12,335 4.0 [1.3-10.0] 3.0 [1.0-8.0] 4.0 [1.2-10.0] 4.0 [1.0-10.5] 4.8 [1.4-12.2]
Serum phosphorus, mg/dL 22,606 5.1 ± 1.5 5.2 ± 1.6 5.2 ± 1.6 5.3 ± 1.7 5.4 ± 1.7
Parathyroid hormone, pg/mL 20,241 218 [114-387] 209 [110-382] 219 [111-399] 222 [109-399] 209 [103-401]
Serum calcium, mg/dL 22,006 8.9 ± 0.8 8.9 ± 0.8 8.9 ± 0.8 8.9 ± 0.8 8.9 ± 0.8
Comorbid conditions
Coronary artery disease 23,119 2,496 (33%) 2,140 (31%) 1,444 (34%) 989 (37%) 584 (36%)
Heart failure 23,080 1,410 (19%) 1,308 (19%) 856 (20%) 655 (24%) 392 (24%)
Cerebrovascular disease 23,113 1,073 (14%) 901 (13%) 580 (14%) 414 (15%) 284 (18%)
Other cardiovascular disease 23,128 1,976 (26%) 1,765 (25%) 1,115 (26%) 789 (29%) 460 (29%)
Cancer (non-skin) 23,051 1,104 (15%) 897 (13%) 543 (13%) 365 (14%) 208 (13%)
Diabetes 23,065 2,932 (39%) 2,727 (39%) 1,795 (43%) 1,171 (44%) 722 (45%)
Gastrointestinal bleeding 22,992 276 (4%) 243 (4%) 175 (4%) 153 (6%) 65 (4%)
Hypertension 23,040 6,543 (86%) 5,954 (86%) 3,608 (86%) 2,324 (86%) 1,379 (86%)
Lung disease 23,103 810 (11%) 638 (9%) 525 (12%) 346 (13%) 209 (13%)
Neurologic disease 23,134 644 (8%) 526 (8%) 348 (8%) 236 (9%) 154 (10%)
Dementia 22,776 61 (1%) 51 (1%) 45 (1%) 21 (1%) 22 (1%)
Non-dementia 23,134 583 (8%) 475 (7%) 303 (7%) 215 (8%) 132 (8%)
Psychiatric disorder 23,116 961 (13%) 812 (12%) 589 (14%) 409 (15%) 264 (16%)
Peripheral vascular disease 23,120 1,746 (23%) 1,420 (20%) 977 (23%) 689 (26%) 412 (26%)
Recurrent cellulitis, gangrene 23,092 544 (7%) 447 (6%) 300 (7%) 233 (9%) 142 (9%)
Hepatitis C 22,960 315 (4%) 373 (5%) 229 (5%) 149 (6%) 108 (7%)
Cirrhosis 23,039 96 (1%) 88 (1%) 69 (2%) 65 (2%) 39 (2%)
Note: Values expressed as mean ± standard deviation, median [interquartile range], or number (percent). ESA dose shown among ESA users. IDWL expressed in
terms of percent body weight. Neurologic disease includes dementia, seizure disorder, cognitive impairment, and Parkinson disease. Psychiatric disorder includes
depression, bipolar disorder, schizophrenia/psychotic disorder, alcohol abuse within past 12 months, and other substance abuse within past 12 months.
Abbreviations: ESA, erythropoiesis-stimulating agent; HD, hemodialysis; IDWL, intradialytic weight loss.
Sukul et alWe used multiple imputation, assuming data were
missing at random, to impute missing covariate values using
the sequential regression multiple imputation method by
IVEware (Institute for Social Research, University of
Michigan).33 Results from 20 such imputed data sets
were combined for the final analysis using Rubin’s for-
mula.34 The proportion of missing data was <5% for all
covariates, with the exception of vascular access (9%)
and serum albumin level (6%). All analyses were con-
ducted using SAS software, version 9.4 (SAS Institute).Kidney Med Vol 3 | Iss 1 | January/February 2021RESULTS
Study Sample
This analysis included 23,264 HD patients who responded
to a survey question asking about the extent the patient
was bothered by itchy skin during the past 4 weeks. We
excluded 11,430 patients for various reasons, mostly due
to survey nonresponse (Fig 1). Included patients tended to
be healthier, for example, fewer comorbid conditions and
better nutritional/inflammatory markers (Table S2).45
Figure 2. Self-reported pruritus, by country. Abbreviations: A/NZ, Australia/New Zealand; Bel, Belgium; Can, Canada; Chi, China;
Fra, France; GCC, Gulf Cooperation Council countries (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates); Ger,
Germany; Ita, Italy; Jpn, Japan; Rus, Russia; Spa, Spain; Swe, Sweden; Tur, Turkey; UK, United Kingdom; US, United States.
Sukul et alDescriptive Data
The proportions of patients not at all, somewhat, moderately,
very much, and extremely bothered by pruritus were 33%,
30%, 18%, 12%, and 7%, respectively. The proportion of
those who were at least moderately bothered by pruritus was
highest in the United Kingdom (47%) and lowest in Ger-
many (27%; Fig 2). The prevalence of moderate to extreme
pruritus among all participants was 37%. Overall, prevalence
was unchanged across DOPPS phases, though there was some
variation by country (Fig S1). Patient characteristics by pru-
ritus severity are summarized in Table 1; patients more
bothered by itchy skin tended to be slightly older with
greater comorbidity, be more likely to dialyze with a cath-
eter, and had higher serum phosphorus levels and lower
hemoglobin and serum albumin levels.
Pruritus and Clinical Outcomes
The adjusted associations between self-reported pruritus and
clinical outcomes are illustrated in Figure 3. Median follow-
up time was 18 (interquartile range, 9-28) months.
Compared with patients who reported being not at all
bothered by itchy skin, patients who were extremely both-
ered had a higher rate of all-cause mortality (hazard ratio
[HR], 1.24, 95% CI, 1.08-1.41; Fig 3A); the HR in the
unadjusted model was 1.59 (95% CI, 1.41-1.81) and was
attenuated by adjustment for several potential confounders
(Table S3). Patients extremely bothered by itching also had
higher rates of CV-related (HR, 1.29; 95% CI, 1.06-1.57)
and infection-related mortality (HR, 1.44; 95% CI, 1.05-
1.96; Fig 3A). The adjusted rates of all-cause, CV-related, and
infection-related hospitalizations were all w20% greater for
patients extremely bothered versus not at all bothered by
itchy skin; the HR for skin-related infections was 1.41 (95%
CI, 0.87-2.27) for extremely versus not at all bothered,
although the precision of this estimate was limited by the low
number of events (Fig 3B). Patients who were extremely46versus not at all bothered by itchy skin also had a greater rate
of hospitalization for mental status change/confusion (HR,
1.84; 95% CI, 1.18-2.87).
Pruritus and Dialysis-Related Outcomes
The HR for withdrawal from dialysis was 1.50 (95% CI,
1.05-2.14) for patients extremely versus not at all both-
ered by itchy skin (Fig 4A). Patients who were extremely
bothered were also more likely to skip dialysis sessions and
less likely to be employed (Fig 4B). A strong monotonic
association between severity of itching and self-reported
length of recovery time following dialysis sessions was
observed (Fig 4B). This association was attenuated after
adjustment for self-reported sleep quality, a potential
mediator, but remained strong: comparing extremely
versus not at all bothered by itchy skin, the prevalence
ratio for recovery time longer than 6 hours was 2.02 (95%
CI, 1.83-2.22) in the adjusted model and 1.63 (95% CI,
1.48-1.81) after additional adjustment for sleep quality.
Pruritus and PROs
Self-reported pruritus was strongly associated with both
physical and mental components of HR-QoL: PCS and MCS
scores were each progressively lower as the severity of
pruritus increased (Fig 5A). Mean PCS and MCS scores were
39.2 ± 11.0 (standard deviation) and 48.3 ± 11.4 in patients
who were not at all bothered by itchy skin. Compared with
this reference group, PCS scores were 6.7 (95% CI, 6.1-7.2)
points lower and MCS scores were 9.1 (95% CI, 8.4-9.8)
points lower for patients extremely bothered by itchy skin.
Other PROswere also strongly andmonotonically associated
with pruritus; the prevalence of depressive symptoms (CES-
D score ≥ 10), poor sleep quality, being bothered by faint-
ness/dizziness, and being bothered by feeling washed out/
drained was 2 to 3 times higher among patients extremely
versus not at all bothered by itchy skin (Fig 5B).Kidney Med Vol 3 | Iss 1 | January/February 2021
Figure 3. Association of pruritus with all-cause and cause-specific (A) mortality and (B) hospitalization. Cox regression models
stratified by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and country; adjustments: age, sex, end-stage kidney
disease vintage, 15 comorbid conditions, postdialysis weight, albumin level, hemoglobin level, phosphorus level, and catheter use.
Sukul et alDISCUSSION
In this international evaluation of more than 20,000 HD
patients, we found that pruritus was common, affecting
37% of patients; associated with higher risk for hospitali-
zations and death; and associated with higher rates of
withdrawal from dialysis and missing scheduled dialysis
treatments and lower rates of employment. Additionally,
progressively more severe pruritus was strongly and
monotonically associated with longer recovery time from
dialysis sessions, self-reported depression, self-reported
restless sleep, and progressively poorer self-reported
mental and physical HR-QoL.Kidney Med Vol 3 | Iss 1 | January/February 2021The prevalence of pruritus has declined over the years in
the DOPPS, from a 46% prevalence of moderate to extreme
pruritus in phase 1 (1996-2001)4 to 37% in phases 4 to 6
(2009-2018), which is shown in this study. The preva-
lence among phases 4 to 6 has been relatively stable, with
some country variation (Fig S1).
Patients more bothered by itchy skin tended to be
slightly older, with greater comorbidity, and were more
likely to dialyze with a central venous catheter. They also
had lower hemoglobin levels, were treated with higher
doses of an erythropoiesis-stimulating agent,7 and as in
prior studies, had higher C-reactive protein and lower47
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Figure 4. Pruritus and dialysis-related outcomes. Adjustments: age, sex, end-stage kidney disease vintage, 15 comorbid conditions,
postdialysis weight, albumin level, hemoglobin level, phosphorus level, and catheter use. (A) Cox model stratified by Dialysis Out-
comes and Practice Patterns Study (DOPPS) phase and country; (B) modified Poisson regression with log-link and robust variance
estimator, additionally adjusted for DOPPS phase and country.
Sukul et alserum albumin levels,3,13,35 consistent with the theory
that inflammation may play a role in the pathophysi-
ology of pruritus.19 Dialyzing with a central venous
catheter has been associated with higher levels of
inflammation.36
There was a trend toward higher serum phosphorus
levels with progressive severity of pruritus, as others have
shown.7 However, the data are conflicted regarding the48relationship between pruritus in patients receiving dialysis
and metabolic bone disease parameters, and most studies
have found no relationship between pruritus and phos-
phate levels.4,8,10,18,37-40 There were no notable differ-
ences in parathyroid hormone or calcium levels among the
differing levels of pruritus in our study, nor were there
large differences identified in dialysis vintage, though it
has been shown that patients newer to end-stage kidneyKidney Med Vol 3 | Iss 1 | January/February 2021
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Figure 5. Pruritus and patient-reported outcomes. Adjustments: Dialysis Outcomes and Practice Patterns Study (DOPPS) phase,
country, age, sex, end-stage kidney disease vintage, 15 comorbid conditions, postdialysis weight, albumin level, hemoglobin level,
phosphorus level, and catheter use. (A) Linear mixed models with random facility intercept to account for clustering; (B) modified
Poisson regression with log-link and robust variance estimator. Abbreviations: PCS/MCS, Physical/Mental Component Summary,
derived from the 12-Item Short Form Health Survey.
Sukul et aldisease have lower odds of having moderate to extreme
pruritus.3,12,13
We observed a clear association between extreme pru-
ritus and all-cause and cause-specific mortality. The asso-
ciation with cardiovascular mortality may relate to higher
levels of inflammation in these patients or possibly the
higher prevalence of heart failure, and the infection-related
mortality may relate to derangements in the immune
system of these patients or the presence of a central venousKidney Med Vol 3 | Iss 1 | January/February 2021catheter.36 Those with extreme pruritus had the highest
prevalence of catheter use, which may serve to explain in
part the higher infection-related mortality seen among
those extremely bothered, given the high risk for fatal
infections seen in patients with dialysis catheters.41 The
association between mortality and pruritus in general has
been previously identified.3,12,13 Kimata et al13 showed a
22% higher rate of mortality in the Japanese Dialysis
Outcomes and Practice Patterns Study (JDOPPS) for49
Sukul et alpatients moderately to extremely bothered by pruritus (vs
not bothered), and adjustment for sleep quality did not
serve to explain this association, as it has in other studies.3
We observed a monotonic association between pruritus
severity and all-cause hospitalization, with the strongest
association observed between extreme pruritus and hos-
pitalization due to mental status change/confusion.
However, this should be interpreted with caution because
the percentage of patients with a hospitalization due to
mental status change/confusion was only 1% (event rate,
0.009). Because this model was adjusted for 15 comorbid
conditions (listed in Table 1), these associations are not
likely to be explained by the overall illness of the patient
but may be linked to central nervous system disturbances
associated with pruritus or its treatment.42
It is possible that the association between extreme pru-
ritus and withdrawal from dialysis may be related to the
contribution of pruritus to overall symptom burden, which
is significant among patients receiving HD43,44 and likely
reflected in the large number of patients who withdrew
from dialysis in our study. It may also provide a plausible
explanation for the association observed between extreme
pruritus and missed dialysis treatments, which has been
observed previously.7 Conversely, missing dialysis treat-
ments may itself lead to worsening of symptoms because
prior studies have shown that higher levels of serum urea
nitrogen, a marker of middle-molecule clearance, were
associated with more severe pruritus,12 and increasing Kt/V
led to an improvement in pruritus.45,46 We found that pa-
tients who were extremely (vs not at all) bothered by pru-
ritus had a slightly lower mean Kt/V, though this finding
was not consistent with prior DOPPS analyses3,4 and other
studies have shown no association between Kt/V and pru-
ritus.7,8,12 Missed dialysis treatments have been associated
with increased risk for death,47 and longer interdialytic in-
tervals have been associated with all-cause, cardiac-related,
and infection-related mortality.48 The lower prevalence of
employment among patients with extreme pruritus may also
be linked to the cumulative symptom burden, making it
more difficult to sustain or seek employment.
The progressive increase in the prevalence of longer
postdialysis recovery time with increasing severity of
pruritus, even after adjustment for sleep quality, was
striking. Longer recovery time adds not only to the already
high symptom burden but also to the psychological
burden of living with kidney failure on dialysis14 and may
contribute to missed treatments and withdrawal from
dialysis. The strong monotonic relationship between pru-
ritus and recovery time suggests that there may be a
common neurologic mechanism mediating these symp-
toms that deserves to be further investigated.
Consistent with prior studies, we show that patients
who are more bothered by pruritus have progressively
worse self-reported mental and physical HR-QoL3,7,13 and
depressive symptoms.3,14 In our study, PCS scores were
6.7 (95% CI, 6.1-7.2) points lower and MCS scores were
9.1 (95% CI, 8.5-9.8) points lower for patients extremely50bothered by itchy skin. We regarded 3- to 5-point dif-
ferences in MCS and PCS scores as clinically relevant.49,50
Although pruritus may lead to depressive symptoms, the
reverse is also possible because a longitudinal study by
Yamamoto et al51 found that patients with baseline
depressive symptoms had higher odds of having severe
pruritus when compared with no/mild pruritus (adjusted
odds ratio, 1.78; 95% CI, 1.53-2.07).
We confirm previous findings that pruritus is associated
with poor sleep quality,3,8,13-15 as well as feeling washed
out or drained.3,13 Patients also had a higher likelihood of
dizziness/faintness with progressively greater severity of
pruritus, which may be yet another reason for missing
treatments and/or withdrawing from dialysis.
There are limitations to this study. First, based on the
characteristics of the survey question, this is an observa-
tional study assessing the severity of pruritus at one point in
time and only during the preceding 4 weeks. Although the
change in pruritus severity has been shown over time in the
DOPPS,4 we cannot make inferences in how changes in
pruritus severity may relate to the outcomes in this study.
Though the use of this instrument to measure the severity of
pruritus has previously been published with consistent re-
sults across many years of DOPPS,1,4,18 it has not yet been
formally validated. However, there is much utility in the use
of this 1-question scale compared with other longer scales
to improve the ease and efficiency for both providers and
patients in evaluating this important symptom.
Second, because the severity of pruritus was self-
reported, patients may over- or underreport the true
severity, leading to possible recall and misclassification
bias. Third, the possible bidirectionality of the relationship
between pruritus and cross-sectional PROs (eg, depression,
missed dialysis sessions, and poor sleep quality) limits the
inferences that can be made and does not allow conclu-
sions about cause-effect relationships. Additionally, we did
not include treatments of pruritus in our analyses due to
potential treatment-by-indication bias and therefore
knowledge of how these treatments may relate to the
outcomes in this study remains limited. Finally, there were
11,332 (33%) patients who did not respond to the survey
or complete the pruritus question, and the sample of pa-
tients who responded to the survey was slightly healthier
than nonresponders (Table S2), leading to possible
nonresponse bias, and because patients more bothered by
pruritus are more likely to have comorbid conditions, it is
possible that the prevalence of pruritus in our study is
underreported.
Patients with CKD underreport their pruritus for reasons
that include a lack of awareness of its link with CKD and an
acceptance of it as a symptom they must live with.52
Subsequently, health care providers underestimate the
prevalence and severity of pruritus,4 and assessment
practices vary widely among health care providers.52
This study demonstrates the high prevalence of pruri-
tus among patients receiving HD, as well as the strong
associations of pruritus with numerous and diverseKidney Med Vol 3 | Iss 1 | January/February 2021
Sukul et alclinical outcomes, dialysis-related outcomes, and PROs.
The economic burden to dialysis facilities and payers as a
result of pruritus and consequent missed HD sessions,
hospitalizations, and overall health care use are beyond
the scope of this study but deserve further investigation.
Our study confirms the importance of identifying pa-
tients who experience pruritus, particularly those with
severe forms, and underscores the need to identify and
treat patients with pruritus effectively to reduce symp-
tom burden and improve quality of life and possibly
even survival.SUPPLEMENTARY MATERIAL
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